Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor.

Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S.

J Exp Med. 2007 Feb 19;204(2):345-56. Epub 2007 Jan 29.

PMID:
17261634
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.

Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.

Cancer Res. 2006 Feb 1;66(3):1809-17.

PMID:
16452242
[PubMed - indexed for MEDLINE]
Free Article
3.

Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors.

Bundell CS, Jackaman C, Suhrbier A, Robinson BW, Nelson DJ.

Cancer Immunol Immunother. 2006 Aug;55(8):933-47. Epub 2005 Nov 11.

PMID:
16283304
[PubMed - indexed for MEDLINE]
4.

RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing.

Gregerson DS, Lew KL, McPherson SW, Heuss ND, Ferrington DA.

Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5385-94.

PMID:
17122128
[PubMed - indexed for MEDLINE]
Free Article
5.

Suppression of an already established tumor growing through activated mucosal CTLs induced by oral administration of tumor antigen with cholera toxin.

Wakabayashi A, Nakagawa Y, Shimizu M, Moriya K, Nishiyama Y, Takahashi H.

J Immunol. 2008 Mar 15;180(6):4000-10.

PMID:
18322209
[PubMed - indexed for MEDLINE]
Free Article
6.

Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.

Janicki CN, Jenkinson SR, Williams NA, Morgan DJ.

Cancer Res. 2008 Apr 15;68(8):2993-3000. doi: 10.1158/0008-5472.CAN-07-5008.

PMID:
18413769
[PubMed - indexed for MEDLINE]
Free Article
7.

Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.

Boonman ZF, van Mierlo GJ, Fransen MF, Franken KL, Offringa R, Melief CJ, Jager MJ, Toes RE.

J Immunol. 2004 Feb 1;172(3):1567-74.

PMID:
14734736
[PubMed - indexed for MEDLINE]
Free Article
8.

Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation.

Ali S, Ahmad M, Lynam J, Rees RC, Brown N.

Int J Cancer. 2004 Jun 10;110(2):239-44.

PMID:
15069688
[PubMed - indexed for MEDLINE]
9.

The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses.

Sartorius R, Pisu P, D'Apice L, Pizzella L, Romano C, Cortese G, Giorgini A, Santoni A, Velotti F, De Berardinis P.

J Immunol. 2008 Mar 15;180(6):3719-28.

PMID:
18322177
[PubMed - indexed for MEDLINE]
Free Article
10.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
[PubMed - indexed for MEDLINE]
11.

Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.

Savage P, Millrain M, Dimakou S, Stebbing J, Dyson J.

Tumour Biol. 2007;28(2):70-6. Epub 2007 Jan 29.

PMID:
17264539
[PubMed - indexed for MEDLINE]
12.

Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.

Xu WL, Li SL, Wen M, Wen JY, Han J, Zhang HZ, Gao F, Cai JH.

Chin Med J (Engl). 2013 Aug;126(16):3019-25.

PMID:
23981604
[PubMed - indexed for MEDLINE]
13.

Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.

Buonocore S, Haddou NO, Moore F, Florquin S, Paulart F, Heirman C, Thielemans K, Goldman M, Flamand V.

J Leukoc Biol. 2008 Sep;84(3):713-20. doi: 10.1189/jlb.0108075. Epub 2008 Jun 20.

PMID:
18567840
[PubMed - indexed for MEDLINE]
Free Article
14.

Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.

Zirlik KM, Zahrieh D, Neuberg D, Gribben JG.

Blood. 2006 Dec 1;108(12):3865-70. Epub 2006 Aug 10.

PMID:
16902144
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.

Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG.

J Immunother. 2008 Feb-Mar;31(2):132-47. doi: 10.1097/CJI.0b013e31815b69c8.

PMID:
18481383
[PubMed - indexed for MEDLINE]
16.

Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.

Bioley G, Guillaume P, Luescher I, Bhardwaj N, Mears G, Old L, Valmori D, Ayyoub M.

J Immunother. 2009 Feb-Mar;32(2):161-8. doi: 10.1097/CJI.0b013e31819302f6.

PMID:
19238015
[PubMed - indexed for MEDLINE]
17.

Ly49D engagement on T lymphocytes induces TCR-independent activation and CD8 effector functions that control tumor growth.

Merck E, Voyle RB, MacDonald HR.

J Immunol. 2009 Jan 1;182(1):183-92.

PMID:
19109149
[PubMed - indexed for MEDLINE]
Free Article
18.

Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells.

Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H, Roy EJ.

J Immunol. 2009 Aug 1;183(3):1828-37. doi: 10.4049/jimmunol.0802322. Epub 2009 Jul 10.

PMID:
19592642
[PubMed - indexed for MEDLINE]
Free Article
19.

The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.

Riquelme E, Carreño LJ, González PA, Kalergis AM.

Eur J Immunol. 2009 Aug;39(8):2259-69. doi: 10.1002/eji.200939341.

PMID:
19637198
[PubMed - indexed for MEDLINE]
20.

[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].

Yang B, He Y, Sun DL, Zou Y, Qin XH, Huang BH.

Zhonghua Yi Xue Za Zhi. 2008 Jul 22;88(28):1956-60. Chinese.

PMID:
19062734
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk